



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 14190

**Title:** Is sorafenib the almighty therapy for the patients with advanced hepatocellular carcinoma invading portal vein?

**Reviewer’s code:** 02936280

**Reviewer’s country:** China

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-23 19:28

**Date reviewed:** 2014-10-06 12:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

This work proposes a review on various treatment strategies for the patients with hepatocellular carcinoma and portal vein invasion. It is a topic of interest to the researchers in the related areas but the paper needs very significant improvement before acceptance for publication. My detailed comments are as follows:

1. The title of the paper is very misleading because the data shown in the manuscript are not directly related to the safety or efficacy of sorafenib in patients who have HCC with PV invasion. Review on the directly relevant references will be more helpful for the reader.
2. The author should accentuate his own opinions in this manuscript, rather than a simple list of documents. Try to discuss the best individualized treatment plan for different patients with hepatocellular carcinoma and portal vein invasion in this paper in more clear, write one section to define the problem.
3. Since outcomes of therapies can be quite different across tumor stages and different location and extent of PVTT, the author should review the available evidence supporting the potential roles of different treatment strategies in the different stages of HCC.
4. The authors have shown the survival benefits of the various treatment strategies in patients with advanced HCC with



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

PVTT. However, it should also be noted that the other three important parameters, efficacy, tolerance and cost, are taken into consideration. 5. The conclusion section should include the general treatment recommendations for patients with HCC and PVTT. There are, however, too many references in this manuscript.



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 14190

**Title:** Is sorafenib the almighty therapy for the patients with advanced hepatocellular carcinoma invading portal vein?

**Reviewer's code:** 02527419

**Reviewer's country:** Taiwan

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-23 19:28

**Date reviewed:** 2014-11-17 17:41

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

**COMMENTS TO AUTHORS**

General Comments: This is a generally well-written manuscript, which reviewed various treatment strategies for patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). I listed my comments as below: Comments: 1. The author described several treatment strategies, including sorafenib, TACE, TARE, HAI chemotherapy, RFA, percutaneous laser ablation, surgery, external beam radiotherapy and combined treatment for patients with HCC and PVTT. Can the author make a table to summarize and compare the difference between these treatment strategies? 2. In page 5, line 13, please change EHS to extrahepatic spread (EHS).